Mepolizumab induced changes in nasal methylome and transcriptome to predict response in asthma

[1,2]Kamini Rakkar, [1,3]Yik Lam Pang, [1,2]Poojitha Rajasekar, [1,2]Michael A Portelli, [1,2]Robert J Hall, [1,2]Rachel L Clifford, [1,3]Dominick Shaw and [1,2]Ian Sayers

[1]Centre for Respiratory Research, National Institute for Health Research Nottingham, Biomedical Research Centre, School of Medicine, [2]Nottingham University Biodiscovery Institute & [3]Clinical Sciences Building, City Hospital, University of Nottingham, Nottingham, United Kingdom

Corresponding author

Kamini Rakkar

Biodiscovery Institute, Science Road, University of Nottingham, NG7 2RD

kamini.rakkar2@nottingham.ac.uk

Contributions

IS, DS and YLP designed the study. KR processed samples, extracted the RNA and DNA and analysed the data. PR and RLC co-analysed the DNA methylation data. MAP and RH co-analysed the RNA sequencing data. All authors contributed to the writing of the manuscript.

Sources of funding

Nottingham NIHR Biomedical Research Centre and Nottingham Universities Hospitals Charity. RC was funded by University of Nottingham Anne McLaren fellowship.

Running title: Mepolizumab changes gene expression in the nose

Descriptor: Asthma Genetics

Total word count: 3237

Abstract

Rationale

Mepolizumab is effective for a subset of severe asthma patients in reducing exacerbation frequency. Discovery of a predictive/early marker accurately identifying patients that will have a long-term beneficial clinical response would enable targeting of treatment.

Objectives

We aimed to characterise the nasal methylome and transcriptome post Mepolizumab and identify signatures related to responder/non-responder status.

Methods

Nasal brushes were taken at baseline (pre-drug) and following 3 months of treatment with Mepolizumab from patients with severe asthma. Both DNA and RNA were extracted. Gene expression was investigated using poly-A RNA sequencing (25M reads) and DNA methylation analysed using the EPIC Array.

Measurements and Main Results

27 paired samples were included, 17 patients were clinical responders and 10 were non-responders at one year. Differential gene expression and DNA methylation analyses identified 6719 genes and 53 CpG sites respectively that changed in response to Mepolizumab. There were 1784 genes which were unique to responders and 893 genes unique to non-responders. Pathway analyses revealed unique gene expression signatures. Respiratory disease associations and regulators of ongoing T2 inflammation pathway were still active in non-responders, and there was an inhibition of neutrophil activation pathways in responders.

Conclusions

There was a significant change in both the transcriptome and methylome in the nasal epithelium in patients three months post-Mepolizumab therapy suggesting broad effects on the airway epithelium in severe asthma. Responder and non-responder group analyses indicate there is a responder-specific gene expression profile that may aid in predicting response at one year.

Abstract word count: 244

Key words: Genetics, Methylation, Interleukin-5, Inflammation, Airway

Introduction

Asthma affects an estimated 300 million people worldwide and was responsible for 21.6 million disability-adjusted life years in 2019 (1). Globally, severe asthma affects between 3-10% of all patients with asthma (2). In severe asthma, symptoms are usually uncontrolled and exacerbation frequency is high, despite the high dose of medication, including inhaled and oral corticosteroids (2). For some, monoclonal antibody therapy is an option and has been used successfully in several large studies, reducing exacerbation frequency and maintenance oral corticosteroid use (3).

Mepolizumab is an injectable anti-IL5 monoclonal antibody, that prevents the binding of IL5 to its surface receptor on eosinophils (4). It reduces exacerbation frequency and steroid burden (5), however the impact on the airway, particularly at the gene level has not been investigated. In addition, typically a third of patients fail to respond to treatment as seen in real-world studies (6). In the UK, current National Institute for Health and Care Excellence (NICE) guidelines determine efficacy after one year of treatment, based on a clinically significant reduction in exacerbations or continuous oral corticosteroid use (TA671 2021). For patients who do not respond, the duration of medication burden is unnecessary and prevents switching to another monoclonal antibody class, of which there are several. It also costs the NHS time and money.

With additional anti-IL5/IL5R therapies (Reslizumab) and Benralizumab and other biologics targeting separate pathways such as Omalizumab (anti-IgE) and Dupilumab (anti-IL4 and IL13) also available, it is important to investigate biomarkers which may be able to predict early responses to a specific drug, and therefore enable better pharmacological management of patients. Furthermore, investigation of molecular mechanisms may uncover why some patients do not respond to treatment and provide greater understanding of asthma.

Transcriptomic analysis of the airway epithelium is proving a useful tool to both understand asthma pathogenesis and the molecular characterization of responders to specific drugs such as inhaled corticosteroids (7). More recently, the nasal epithelium has shown utility in understanding asthma and drug responses (8) and provides an easy but relevant option in investigating molecular mechanisms of the airway epithelium.

We aimed to explore any changes in gene expression and/or DNA methylation in response to Mepolizumab therapy in the nasal epithelium to provide novel drug mechanistic insight. Furthermore, we aimed to detect a predictive or early gene expression and/or DNA methylation signature that could identify responders or non-responders and therefore enable Mepolizumab therapy to be targeted to those most likely to benefit. Asthma has previously been defined with respect to Type 1 (T1) or Type 2 (T2) inflammation, characterised by high neutrophil (T1) or high eosinophil, immunoglobulin E and fractional exhaled nitric oxide (T2) levels. However new data is suggesting a more nuanced approach is required, a statement supported by this study. Our findings suggest there is a significant transcriptional response to Mepolizumab in the nasal epithelium which is, at least in part, mediated by changes in DNA methylation. We also identified a unique gene expression signature in patients that had a clinically significant response at one year.

Methods

Full methods and statistical analyses are listed in the Supplement. Flow diagram indicating sample and analysis pipeline is in Figure 1.

Recruitment

The PROCLAIM study (Poor Response tO monoClonaL therApy In asthMa) enrolled 42 patients with severe asthma who matched the UK National Health Service (NHS) criteria for receiving Mepolizumab (TA431). Patients were recruited between January 2019 and June 2020. The study was approved by the Medical Ethics Committee (REC18/EM/0268). 27 patients' data was used in this analysis due to patient withdrawal (4 patients) and unavailability of matched nasal brush samples for baseline and 3 months post-Mepolizumab treatment (11 patients).

Sample collection

Nasal brushes were taken at baseline (pre-drug) and 3-months of Mepolizumab treatment. RNA and DNA were extracted with a dual RNA/DNA Purification (Norgen Biotek Corp.).

Responder group allocation

Responders were defined as patients who had a 50% reduction in oral corticoid steroid use or 50% reduction in exacerbation frequency after one year of Mepolizumab therapy as per NICE guidelines TA431 (2017). For consistency and adherence to protocol, we did not alter the study's definition of clinical response when NICE published the new TA671 (2021).

RNA sequencing

Gene expression was determined through stranded paired end polyA RNA sequencing (Oxford Genomics) using Illumina v1.5 chemistry and the NovaSeq6000 at a minimum of 25M reads per sample.

DNA methylation

DNA methylation was determined through the Illumina Infinium MethylationEPIC Bead Chip Array (Diagenode) which covers 850,000 methylation sites.

Results

Responders and non-responders show no significant differences in clinical or demographic features at baseline

The patient cohort had a median age of 57 years and predominance of females (62%) in line with other severe asthma cohorts (9). As expected, patients had at least one comorbidity (90%) and asthma control questionnaire (ACQ6) scores were in line with severe asthma patients with average scores >3. Similarly, clinical features such as lung function measured by FEV_1/FVC ratios are <70% and eosinophil levels are 0.55 $x10^9$/L or higher, indicative of severe asthma patients (Table 1).

The nasal cell composition following Mepolizumab treatment is unaltered

After filtering and normalisation 684,807 probes were used in the methylation analysis (Supplement Figure 1). A reference dataset (EpiDISH) was used to determine indirectly the cell type composition of the nasal brush samples using DNA methylation data. Epithelial cell, fibroblast, and immune cell markers were analysed. There were no significant differences in inferred cell type composition between baseline and post-Mepolizumab therapy and between responder and non-responder groups (Supplement Figure 2). Epithelial cells were the largest observed population of cells.

Mepolizumab induces significant changes in gene expression in the nasal epithelium

Principal component analysis of gene expression shows distinct clustering of patients post-Mepolizumab therapy (red dots) compared to a more heterogenous distribution pre-treatment (blue dots, Figure 2A). A total of 2547 genes were down-regulated, and 4172 genes were up-regulated following 3 months treatment in all patients (Figure 2B). Expression values of these genes in each patient sample distinctly shows the changes in expression after therapy (Figure 2C). A list of differentially expressed genes is provided (Supplement Table 1).

Mepolizumab-induced changes in gene expression are associated with downstream viral disease

Disease association pathway analysis of the gene expression changes following Mepolizumab therapy, identified significant associations with multiple viral related pathways e.g. viral infection, release of lentivirus. Other significant associations were related to inflammatory diseases such as psoriasis and immune related inflammatory disease. A full list of disease associations is provided (Supplement Table 2).

Mepolizumab-induced changes in gene expression are associated with inflammation, xenobiotic metabolism and fibrosis pathways

Pathway analysis of the gene expression changes following Mepolizumab therapy show evidence of suppression of inflammatory pathways. For example, pathways related to crosstalk between dendritic cells and natural killer cells, “type 1 diabetes and interferon signalling were observed. There is also evidence of activation of fibrotic pathways e.g. FGF signalling, epithelial mesenchymal transition and pulmonary fibrosis idiopathic signalling pathways (Figure 2D). Full pathway analysis is provided (Supplement Table 3).

Mepolizumab-induced changes in gene expression are associated with upstream cytokine activity

Upstream analysis is used to identify regulators that may be responsible for the observed gene expression changes. Mepolizumab-induced changes in gene expression were identified to, at least in part, be due to activity changes in asthma related cytokines such as IL13, IFN-alpha, IL1-beta and TNF-alpha (Figure 3A, orange circles) and transcription regulators, for example SP1 and STAT1 (blue circles). Full upstream regulator analysis is provided (Supplement Table 4).

Mepolizumab-induced changes in gene expression are associated with a decrease in downstream neutrophil activation

Downstream functional effects analysis is used to identify functional pathways expected to be activated or inhibited, given the observed expression in the dataset. Mepolizumab-induced gene expression changes show a significant association with an inhibition of activation of peripheral blood neutrophils pathways (z-score of -2.9, Figure 3B). A general activation in gene expression (Figure 3B, red circles) and cellular assembly pathways (green circles) is also observed. Full downstream functional effects analysis is provided (Supplement Table 5).

There are significant differences in gene expression between responders and non-responders after Mepolizumab therapy

Differential analysis between baseline and post-Mepolizumab treatment gene expression in the responder group alone resulted in 1142 down regulated and 2145 up-regulated genes (adjusted p-value <0.05) (Figure 4A), while 1012 down-regulated and 1382 up-regulated genes were identified in the non-responder group alone (adjusted p-value <0.05) (Figure 4B). Of these, 1784 genes were unique to responders alone and 893 genes were unique to non-responders alone, with the remaining 1500 genes (36%) overlapping (Figure 4C). However, some caution should be used in interpretation due to the differences in responder (n=17)/non-responder (n=10) group sample size. At baseline we found no significant differences in gene expression between responders and non-responders. A list of unique differentially expressed genes for the separate responder or non-responder groups is provided (Supplement Tables 6 and 7).

Mepolizumab-induced gene expression changes are associated with downstream respiratory disease in non-responders but not responders

Disease association pathway analysis of separate responder and non-responder Mepolizumab-induced changes in gene expression, commonly tagged broad terms such as fibrosis, viral infection, immune mediated inflammatory disease and eosinophilia. A large group of specific respiratory and auto-immune disease associations were only present in the non-responder group (Figure 4D). Full disease analysis is provided (Supplement Table 8).

Mepolizumab-induced changes in gene expression are associated with upstream cytokine activity in non-responders

Upstream regulator analysis in separate responder and non-responder groups showed an overlap of 170 regulators (adjusted p-value <0.05). Mepolizumab-induced gene expression changes were associated with an activation of upstream regulators of TSLP, IL4 and IL33 cytokines in the non-responder dataset only (Figure 5A, orange circles) suggesting there is ongoing T2 inflammation in the airways. Full upstream regulator analysis is provided (Supplement Table 9).

Mepolizumab-induced changes in gene expression are associated with a decrease in downstream neutrophil activation in responders but not non-responders

Mepolizumab induced gene expression changes drove different downstream pathways in responder and non-responder datasets. A responder signature included suppression of pathways related to activation of peripheral blood neutrophils, quantity of superoxide, apoptosis and cell death of epithelial cells and increases pathways related to intracellular assembly pathways including; microtubule dynamics, organization of cytoplasm and cytoskeleton (Figure 5B, triangles). In the non-responder dataset, there was an inhibition in pathways related to cellular homeostasis, adhesion of immune cells, cell survival viability. Pathways related to cell death of immune cells and fibroblast development were modestly activated (Figure 5B, circles). Full downstream functional effects analysis is provided (Supplement Table 10).

Mepolizumab treatment induces changes in DNA methylation in the nasal epithelium

Principal component analysis (Figure 6A) of DNA methylation did not show any distinct clustering of patients post-Mepolizumab therapy (red dots) compared to baseline (blue dots) in contrast to the gene expression data. A total of 53 CpG sites were differentially methylated (FDR $p<0.05$) after 3 months of Mepolizumab treatment (Figure 6B). Methylation values of these sites in each patient sample show the changes in DNA methylation after therapy (Figure 6C). Full list of differentially methylated CpG sites is provided (Supplement Table 11).

Genes which correlate with Mepolizumab-induced changes in DNA methylation are associated with primary ciliary dyskinesia, cellular assembly, movement and metabolism

There were 1452 significant DNA methylation and gene expression correlations. This involved 42 (79%) of the differential methylated sites and 838 (12%) of differentially expressed genes (Figure 7A and B). Disease pathway analysis showed a strong association with respiratory diseases such as primary ciliary dyskinesia, chronic familial respiratory disorder and sinus disorder (Figure 7C). Full correlation and disease analyses is provided (Supplement Tables 12 and 13).

Downstream function analysis of correlated genes show association with pathways predominantly involved in cell movement, migration of cells, organisation of the cytoplasm and metabolism of reactive oxygen species (Figure 7D). Full downstream functional effects analysis is provided (Supplement Table 14).

No significant changes in DNA methylation were seen when comparing responder and non-responder methylation profiles at baseline or when comparing baseline and post-Mepolizumab therapy DNA methylation in responder or non-responder datasets separately.

Discussion

This study set out to identify changes in gene expression and/or DNA methylation in response to Mepolizumab in the nasal epithelium in patients with severe asthma to provide novel understanding of drug mechanisms, and to test the hypothesis that there may be an identifiable gene signature present at three months that predicts clinical response at one year. Overall, these data suggest that 3 months of Mepolizumab treatment significantly impacts airway epithelial gene expression and, by inference, homeostasis in severe asthma, leading to a potentially more homogeneous profile than at recruitment. Of note, there was a suppression of inflammation pathways, particularly those related to viruses/interferons. Interestingly, when gene expression analyses were completed separately in responders/non-responders, distinct gene expression profiles were identified. Non-responders exhibited, amongst others, elevated upstream activation of IL33, TSLP and IL4, suggesting ongoing T2 inflammation remains following treatment, furthermore, respiratory disease associations also remain. In contrast, in responders, gene expression associated with a decrease in downstream neutrophil activation was a feature. Finally, we also investigated the effect of Mepolizumab on DNA methylation and illustrate that a large proportion of differential methylation post treatment is associated with gene expression differences demonstrating that methylation at least in part contributes to the mechanisms driving altered gene expression. In post-Mepolizumab samples *TET3* also showed a slight but significant increase in expression (logFC 0.25) indicating Mepolizumab may be altering DNA methylation mechanisms. These novel data provide a unique insight into the impact of Mepolizumab in the airway epithelium and highlight potential signatures found in the clinical responder population.

To our knowledge, this is the first study to investigate gene expression and DNA methylation in the nasal epithelium of severe adult asthma patients in response to Mepolizumab treatment. Mepolizumab has previously been shown to induce elevated tight junction formation and cilium organisational genes in nasal scrapings from aspirin exacerbated respiratory disease patients (10), which we have also observed in our own results, especially those correlated with DNA methylation. In this study, we show that Mepolizumab has a broad effect on nasal epithelial gene expression, providing new insight and potentially confirming the hypothesis that there is an anti-inflammatory effect on the airway epithelium. This anti-inflammatory property is driven not only by the observation that several chemokine genes were supressed, including CXCL5, 10 and 11, all known to be important in asthma, but also through more novel findings, e.g. changes in pathways related to fibrosis.

When looking at Mepolizumab-induced gene changes in all asthma patients, cytokines such as IL13, and IL1RN are activated in pathways predicted to explain these gene expression changes, whereas IFN-alpha and -gamma, IL1-alpha and -beta, IL17A, and TNF-alpha are predicted to be inhibited. Other studies have also shown cytokines to be affected by Mepolizumab therapy. One study found IL1 receptor antagonist to be increased after 4 weeks of Mepolizumab therapy (11) whereas in another study serum levels of TSLP were reduced after Mepolizumab therapy (12).

The current study has taken a molecular approach in investigating a response signature. Other studies have focussed on genetic associations (13), blood (14) or sputum biomarkers (15), clinical features such as lung function (16) or even characterising super responders (17) but

have found limited evidence. However, ACQ scores have been shown to be predictors of response (18).

Explorative analysis into specific responder or non-responder groups alone, shows that, IL4, IL33, and TSLP are activated and IL1-alpha and -beta and IFN-alpha 2 are inhibited in non-responders only. These results indicate that overall non-responders are experiencing a higher degree of inflammation that is both epithelial and inflammatory cell driven. Furthermore, inhibition of IL-1 and IFN activities could indicate inadequate responses to infections and therefore poor outcome (19). This complexity of the cytokine environment requires further investigation and may in part explain differences in responses and may advocate for alternative methods of treatment. Therapies aimed at targeting the upstream epithelial alarmins such as TSLP (Tezepelumab) and IL33 (Itepekimab) may provide an alternative or dual therapy for patients who do not respond to Mepolizumab (20).

Another gene in our study, CCL5, was found to be unique to responders and had a slight decrease in activity (logFC -0.56). This is of particular note as it is a chemoattractant for eosinophils (21). Another chemoattractant CCL4 has been shown to be lower in the blood of responders compared to non-responders at baseline and after 4 weeks of Mepolizumab therapy (22).

As well as cytokines, investigation of alternate immune cells such as neutrophils may also benefit those patients who do not respond to Mepolizumab. Although we did not see a change in neutrophil numbers in the blood post-treatment (data not shown), at the molecular level, Mepolizumab-induced changes in gene expression were associated with a downstream suppression of the neutrophil activation pathway only in patients who responded to treatment. This may provide an additional mechanism of action of Mepolizumab. In a recent study in asthma patients challenged with rhinovirus, Mepolizumab prevented an increase neutrophil numbers and activation in sputum (23). Similarly, in a study of nasal lavage gene expression, a module of genes related to neutrophil chemotaxis, was found to be inversely associated with exacerbations (24).

In the same nasal lavage study, increased expression of epithelium related gene modules was observed after 52 weeks of Mepolizumab therapy and associated with exacerbation (24). Structural, cellular and tissue changes, such as fibrotic pathways, were also associated with Mepolizumab induced gene expression changes in our study, indicating that Mepolizumab may affect cellular structure and possibly airway remodelling. Although there are no current studies that have directly investigated the role of Mepolizumab in airway remodelling, a study looking at Lebrikizumab, which neutralises IL13, suggests it may reduce asthmatic airway remodelling (25). Interestingly these structural cell biology mechanisms are also strongly correlated with changes in DNA methylation. Previous studies have shown differentially methylated regions to be associated with asthma and relevant genes such as IL4 and IL13 (26). DNA methylation changes have also been associated with cytoskeletal remodelling in asthma (27). Collectively these data and our study suggest cellular structural changes and airway remodelling is a key mechanism that needs to be explored further.

This is the first time the effect of Mepolizumab on gene expression and DNA methylation in the nasal epithelium of patients with severe asthma has been studied. We have found that Mepolizumab affects the inflammatory profile, neutrophil activation, and cellular structural mechanisms in the upper airway epithelium. From our explorative responder/non-responder

analysis, our data suggests that there may be an early gene expression signature to indicate response, predominantly related to a reduction in the T2 inflammatory profile in responders but a sustained T2 inflammatory profile in non-responders. However, due to the differences in sample size and therefore statistical power between the responder and non-responder groups, these results need to be interpreted with caution and replication would be of benefit to add confidence to the results but to our knowledge there is no replication cohort with nasal brush samples for which this can be done at the moment. Finally, we have found that changes in DNA methylation associate with gene expression and these are related to cellular assembly, metabolism and movement. Taken together, our data has provided novel molecular insight into the effect of Mepolizumab therapy in severe asthmatic patients and provides a basis for further investigation into molecular mechanisms of response that may lead to a more tailored approach to prescribing.

Data sharing

The RNA sequencing and DNA methylation data will be deposited in a publicly available database upon acceptance for publication. Summary data is available in the supplements.

Declaration of interests

None.

Acknowledgements

Mohammed Ali for his help in administration, recruitment and sample processing. Laura Matthews, Helen Bailey, Carly Clayton, Karina Bingham, and Rebecca M Cooper for their help in sample acquisition and processing.

References

1. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22.
2. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902.
3. Casale TB, Burnette A, Bourdin A, Howarth P, Hahn B, Stach-Klysh A, et al. Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies. Ther Adv Respir Dis. 2022;16:17534666221107313.
4. Fainardi V, Pisi G, Chetta A. Mepolizumab in the treatment of severe eosinophilic asthma. Immunotherapy. 2016;8(1):27-34.
5. Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20(1):179.
6. Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56(4).

7. Kuo CS, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I, et al. A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED. Am J Respir Crit Care Med. 2017;195(4):443-55.
8. Pandey G, Pandey OP, Rogers AJ, Ahsen ME, Hoffman GE, Raby BA, et al. A Nasal Brush-based Classifier of Asthma Identified by Machine Learning Analysis of Nasal RNA Sequence Data. Sci Rep. 2018;8(1):8826.
9. Jackson DJ, Busby J, Pfeffer PE, Menzies-Gow A, Brown T, Gore R, et al. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. Thorax. 2021;76(3):220-7.
10. Buchheit KM, Lewis E, Gakpo D, Hacker J, Sohail A, Taliaferro F, et al. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2021;148(2):574-84.
11. Nowak-Jurek A, Gajewski A, Frachowicz-Guereirro K, Antczak-Marczak M, Gulbas I, Kowalski ML, et al. Cytokines in serum, nasal secretion and exhaled breath condensate during mepolizumab therapy in patients with different phenotypes of severe eosinophilic asthma: A pilot study. Clin Exp Allergy. 2022.
12. Kalinauskaite-Zukauske V, Januskevicius A, Janulaityte I, Miliauskas S, Malakauskas K. Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report. Can Respir J. 2019;2019:8607657.
13. Condreay L, Chiano M, Ortega H, Buchan N, Harris E, Bleecker ER, et al. No genetic association detected with mepolizumab efficacy in severe asthma. Respir Med. 2017;132:178-80.
14. Landi C, Vantaggiato L, Shaba E, Cameli P, Carleo A, d'Alessandro M, et al. Differential redox proteomic profiles of serum from severe asthma patients after one month of benralizumab and mepolizumab treatment. Pulm Pharmacol Ther. 2021;70:102060.
15. Pavord ID, Buhl R, Kraft M, Prazma CM, Price RG, Howarth PH, et al. Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab. ERJ Open Res. 2022;8(2).
16. Lemiere C, Taille C, Lee JK, Smith SG, Mallett S, Albers FC, et al. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials. Respir Res. 2021;22(1):184.
17. Atayik E, Aytekin G. A Single Center Experience of Super-Responders Among Severe Asthma Patients Receiving Treatment with Mepolizumab. Turk Thorac J. 2022;23(5):348-54.
18. Elsey L, Pantin T, Holmes LJ, Tavernier G, Fowler SJ. Outcomes over the first two years of treatment with mepolizumab in severe asthma. Eur Respir J. 2021;58(6).
19. Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24 Suppl 2:S21-S40.
20. Tamari M, Trier AM, Kim BS. Emerging targeted therapeutics underscore immunologic heterogeneity of asthma. J Allergy Clin Immunol. 2021;148(3):719-21.
21. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med. 1992;176(2):587-92.
22. Suzukawa M, Ohshima N, Tashimo H, Asari I, Kobayashi N, Shoji S, et al. A Low Serum CCL4/MIP-1beta Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab. Intern Med. 2020;59(22):2849-55.
23. Sabogal Pineros YS, Bal SM, van de Pol MA, Dierdorp BS, Dekker T, Dijkhuis A, et al. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study. Am J Respir Crit Care Med. 2019;199(4):508-17.

24. Jackson DJ, Bacharier LB, Gergen PJ, Gagalis L, Calatroni A, Wellford S, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet. 2022;400(10351):502-11.
25. Austin CD, Gonzalez Edick M, Ferrando RE, Solon M, Baca M, Mesh K, et al. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Clin Exp Allergy. 2020;50(12):1342-51.
26. Legaki E, Arsenis C, Taka S, Papadopoulos NG. DNA methylation biomarkers in asthma and rhinitis: Are we there yet? Clin Transl Allergy. 2022;12(3):e12131.
27. Wawrzyniak P, Krawczyk K, Acharya S, Tan G, Wawrzyniak M, Karouzakis E, et al. Inhibition of CpG methylation improves the barrier integrity of bronchial epithelial cells in asthma. Allergy. 2021;76(6):1864-8.

Table 1. Clinical and demographic features of patients at baseline and/or 12-months (as indicated) and comparison between responder and non-responder groups.

	All patients	**Non-responder (n=10)**	**Responder (n=17)**	**P value**
Sex / Female no. (%)	17 (62.1)	8 (80)	9 (52.9)	0.16†
Age / years (IQR)	57.38 (38.40, 65.27)	58.55 (44.58, 68.96)	57.38 (38.24, 64.58)	0.55‡
Body mass index (SD)	32.62 (7.35)	32.59 (9.33)	32.83 (6.17)	0.94§
Comorbidity* / yes (%)	24 (89.7)	9 (90)	15 (88.2)	0.89†
Atopic Rhinitis (%)	2 (7.4)	1 (10)	1 (5.9)	0.693†
Smoking never/ex/current (%)	13 (44.8) / 13 (44.8) / 3 (10.3)	6 (60) / 3 (30) / 1 (10)	6 (35.3) / 10 (58.8) / 1 (5.9)	0.35†
Asthma control questionnaire / average score of 6 (SD)	3.28 (1.42)	3.42 (1.62)	3.27 (1.42)	0.81§
Exacerbations / year pre-recruitment (SD)	6.32 (3.19)	5.78 (3.23)	5.82 (2.40)	0.97§
Exacerbations / year 12-months post recruitment (SD)	2.67 (2.50)	5.14 (2.91)	1.64 (1.41)	0.02§
OCS at baseline - prednisolone dose/mg (SD)	11.78 (12.85)	16.80 (17.73)	8.82 (8.15)	0.121§
OCS at 12 months – prednisolone dose/mg (SD)	8.36 (12.01)	20.00 (18.71)	4 (3.27)	0.003§
FEV_1 % predicted (SD)	67.64 (22.47)	58.65 (21.53)	69.79 (51.52)	0.24§
FEV_1/FVC (SD)	68.22 (12.24)	65.83 (12.71)	68.64 (12.79)	0.61§
Eosinophils highest in year pre-recruitment / $x10^9$/L (IQR)	0.55 (0.40, 0.71)	0.5 (0.37, 0.72)	0.50 (0.40, 0.70)	0.51‡
White blood cells (IQR)	8.00 (6.66, 9.66)	8.53 (6.85, 9.29)	7.70 (6.36, 10.78)	0.74‡

*Comorbidities defined as anxiety/depression, cancer, deep vein thrombosis, diabetes, eczema, hay fever, hypertension, ischaemic heart disease, pulmonary embolism, reflux or renal failure

†Chi-Square Test, ‡Mann-Whitney U Test, §Independent T-Test,

Figure 1. Study design and analysis workflow for gene expression and DNA methylation data.

(A) Patients were recruited into the PROCLAIM study and nasal brush samples were taken at baseline and 3 months post-Mepolizumab therapy. DNA and RNA was extracted from the same brush. Gene expression was analysed through polyA RNA sequencing and DNA methylation through the EPIC Array. Gene expression and DNA methylation raw data was evaluated as part of quality control, filtered and normalised before differential analysis. (B) A differential analysis was conducted to compare gene expression and DNA methylation differences between baseline and post-Mepolizumab therapy in all paired samples and a pathway analysis was conducted on the differentially expressed genes. Differentially expressed genes and differentially methylated CpG sites were correlated, and a pathway analysis run on the correlated genes (C) A differential analysis was conducted to compare gene expression and DNA methylation differences between baseline and post-Mepolizumab therapy in either responder or non-responder paired samples alone and pathway analyses were conducted on the differentially expressed genes. An adjusted p value cut off of <0.05 was applied for all data.

Figure 2. Mepolizumab induces gene expression changes in the nasal epithelium of severe asthma patients.

(A) Principal component analysis shows clustering of patients' gene expression after Mepolizumab therapy. (B) Volcano plot of baseline vs post-Mepolizumab differential gene expression in all subjects. (C) Heatmap of the differentially expressed genes grouped into baseline and post-Mepolizumab blocks. (D) Pathways associated with Mepolizumab-induced gene expression changes. An adjusted p value of <0.05 was applied for all data.

Figure 3. Mepolizumab-induced gene expression changes are associated with cytokine activity.

(A) A bubble plot of upstream regulator associations with Mepolizumab-induced gene expression. Upstream regulators are plotted according to p-value and z-score, with the size of the bubble indicating the number of genes in the dataset affected by the regulator. (B) A bubble plot of downstream functional pathway associations with Mepolizumab-induced gene expression. Pathways are plotted according to -log(p-value), due to the broad range of p-values from the data, and z-score, with the size of the bubble indicating the number of genes in the dataset affected by the pathway. An adjusted p value of <0.05 was applied for all data.

Figure 4. There are differences in gene expression between responders and non-responders at one year following 3 months of Mepolizumab treatment.

(A) Volcano plot of baseline vs post-Mepolizumab differential gene expression in responders alone. (B) Volcano plot of baseline vs post-Mepolizumab differential gene expression in non-responders alone. (C) Venn diagram to show overlap of differentially expressed genes between responder and non-responder groups. (D) Disease associations from pathways

analysis in separate responder and non-responder groups. Diseases have been grouped into type. Diseases circled in yellow indicate associations common to both responder and non-responder groups. Purple rectangles indicate associations found in the non-responder group only. Due to a large number of disease associations only auto-immune, infectious, inflammatory, or respiratory diseases have been shown. There were no associations found in the responder group alone. An adjusted p value of <0.05 was applied for all data.

Figure 5. Specific differentially expressed genes post-Mepolizumab therapy are associated with an increase in upstream cytokine regulators in non-responders and an increase in intracellular assembly pathways in responders.

(A) A bubble plot of upstream regulator associations which were unique to responders or non-responders (associations common to both groups not shown). Upstream regulators are plotted according to -log(p-value), due to the broad range of p-values from the data, and z-score, with the size of the bubble indicating the number of genes in the dataset affected by the regulator. (B) A bubble plot of downstream functional pathway associations which were unique to responders or non-responders (associations common to both groups not shown). Pathways are plotted according to -log(p-value), due to the broad range of p-values from the data, and z-score, with the size of the bubble indicating the number of genes in the dataset affected by the pathway. An adjusted p value of <0.05 was applied for all data.

Figure 6. Mepolizumab induces DNA methylation changes in the nasal epithelium of severe asthma patients.

(A) Principal component analysis shows no clustering of patients' DNA methylation profiles after Mepolizumab therapy. (B) Volcano plot of baseline vs post-Mepolizumab differential DNA methylation. (C) Heatmap of the differentially methylated CpG sites grouped into baseline and post-Mepolizumab blocks. An adjusted p value of <0.05 was applied for all data.

Figure 7. Mepolizumab induced changes in gene expression and DNA methylation correlate with each other.

(A) Representative correlations between 3 different genes and correlated CpG sites. Blue dots show samples at baseline and red dots show samples post-Mepolizumab therapy. (B) Plot of all CpG site and gene correlations. Each dot represents a correlation between and CpG site and gene. (C) Diseases associated with 838 differentially expressed genes which were correlated with 42 of the differentially methylated CpG. (D) Downstream functional pathways associated with these 838 genes. Pathways have been grouped into types and the number of genes in each pathway are in brackets. An adjusted p value of <0.05 was applied for all data.


A
Patient recruitment and sample processing
Patients recruited
Nasal swabs taken at baseline (pre-Mepolizumab) and at 3 months of Mepolizumab treatment
Nasal swab processed to cell pellet and stored at -80 °C
DNA and RNA extraction using dual kit
RNA – gene expression
polyA RNA sequencing 25M reads
Alignment to GRCh37.87 (STAR)
Filtering and normalisation (edgeR)
Differential gene expression (limma)
DNA – methylation
EPIC array 850k CpG sites
Normalisation, probe filtering and batch effect correction (funnorm, combat)
Differential CpG site methylation (limma)
B
All samples
Baseline vs Post-Mepolizumab
27 baseline and 27 matched post-Mepolizumab samples for paired analysis
6719 differentially expressed genes and 53 differentially methylated CpG sites (adjusted p <0.05)
Pathway analysis of differentially expressed genes
Correlation analysis of gene expression and DNA methylation
Pathway analysis of 838 correlated genes
C
Responders only
Non-Responders only
Baseline vs Post-Mepolizumab
17 Responder and 10 non-responder samples for paired analysis within each group.
3287 differentially expressed genes in responder group and 2394 in non-responder group (adjusted p <0.05). No differentially methylated CpG sites.
Venn diagram to identify unique and common genes
Pathway Analysis on differentially expressed genes for responders and non-responders
Identification of unique and common pathways/mechanisms/regulators.


A
PC2
PC1
Baseline
Post Mepolizumab


B
2547 genes down-regulated, 4172 genes up-regulated
− Log10 P
log Fold Change
FMO2
FAM21A
HMGB3
SPRED1
NOTCH1
FLNA
BIRC3
B3GALNT2
SOGA1
SPARCL1
COL6A1
SLC5A5
TMSB10
C14orf159
IL33
MMP10
METTL21EP
CCL20
GATA3
PTP4A2
RASSF9
CSRNP3
RP11-706O15.3
GLRX
KRIT1
MKL2
COL4A6
WSCD2
PLD1
ADCY9
AJUBA
FOXL1
MDGA1
LINC00689
DMBT1
RIMBP3
FCGBP
HLA-DQA2
NPBWR1
CXCL9
CSF3
DOK6
LHX6
CXCL10
RP11-707O23.5
FN1
GSTM1
MEG3


C
Row Z-Score
Genes
Baseline
Post-Mepolizumab


D
Pulmonary Fibrosis Idiopathic Signaling Pathway
FGF Signaling
Xenobiotic Metabolism CAR Signaling Pathway
Regulation Of The Epithelial Mesenchymal Transition In Development Pathway
Regulation Of The Epithelial Mesenchymal Transition By Growth Factors Pathway
Xenobiotic Metabolism AHR Signaling Pathway
Lysine Degradation II
Xenobiotic Metabolism PXR Signaling Pathway
Role of BRCA1 in DNA Damage Response
NF-kappaB Signaling
HER-2 Signaling in Breast Cancer
ILK Signaling
Lysine Degradation V
CMP-N-acetylneuraminate Biosynthesis I (Eukaryotes)
Crosstalk between Dendritic Cells and Natural Killer Cells
Ferroptosis Signaling Pathway
Type I Diabetes Mellitus Signaling
Endocannabinoid Cancer Inhibition Pathway
Interferon Signaling
Autophagy
z-score > 2 (activation)
z-score < -2 (inhibition)
Number of genes

A


Number of Genes
50
100
150
p-value
z-score
0.05
0.04
0.03
0.02
0.01
0.00
-5.0
-2.5
0.0
2.5
5.0
TP53
SP1
CKAP2L
TCR
TLR9
RNASEH2B
NONO
BTK
FOXC1
IL1RN
STAT1
NFkB (complex)
IL1B
MRTFB
CG
TREM1
TP63
TREX1
IFNG
INF alpha
IL13
TNF alpha
TGFB1
cytokine
kinase
transcription regulator
receptor
microRNA
other

B


Number of Genes
200
400
600
−log p-value
z-score
6
5
4
3
2
-3
-2
-1
0
1
2
Cell movement
Necrosis
Organization of cytoskeleton
Invasion of cells
Microtubule dynamics
Apoptosis
Migration of cells
Organization of cytoplasm
Formation of cellular protrusions
Angiogenesis
Cell survival
Cell viability
Activation of peripheral blood neutrophils
Development of vasculature
Transcription
Transcription of RNA
Growth of connective tissue
Vasculogenesis
Survival of bacteria
Expression of RNA
Growth of epithelial tissue
Transcription of DNA
cell death
gene expression
cell/tissue development
cellular assembly
cellular movement
other


A
1142 genes down-regulated, 2145 genes up-regulated
FMO2
IL33
SPARCL1
MKL2
METTL21EP
FLNA
ATP2B4
GATA3
CSRNP3
ADAM12
ANK3
TMSB10
FMO6P
COL6A1
RP11-497H16.6
SOGA1
NOTCH1
TOX
RP11-706O15.3
IRX2
C11orf96
RIMBP3
FOXL1
SFRP2
LYPD1
LINC00689
IRX1
IRX4
ISLR
HBA1
DMBT1
LHX6
NPBWR1
HBA2
CSF3
FN1
PNLIPRP3
MEG3
– Log10 P
log Fold Change
B
1012 genes down-regulated, 1382 genes up-regulated
TNIP1
FMO2
NUDT10
BIRC3
FAM21A
SLC5A5
CGNL1
PLD1
COL6A1
CCL20
HLA-DQA1
FLNA
CPNE4
GATA3
FBXO2
WNT2B
RP11-706O15.3
FCGBP
PKD2
NXF2B
LINC00689
RP11-707O23.5
HLA-DQA2
CXCL10
CXCL9
LHX6
GSTM1
CSF3
– Log10 P
log Fold Change
C
all genes
1784 (43%)
1500 (36%)
893 (21%)
up-regulated genes
1236 (47%)
909 (35%)
473 (18%)
down-regulated genes
548 (35%)
591 (38%)
420 (27%)
Responders
Non-responders
D
Auto-immune/Inflammatory
Chronic inflammatory disorder
Chronic large plaque psoriasis
Chronic small plaque psoriasis
Crohn's disease
Dermatitis
Diabetes mellitus
Immunoglobulin deficiency
Inflammatory Bowel Disease
Insulin-dependent diabetes mellitus
Psoriasis
Rheumatic Disease
Rheumatoid arthritis
Severe inflammatory disorder
Eosinophilia
Immune mediated inflammatory disease
Systemic autoimmune syndrome
Pathogenic
Quantity of virus
Replication of virus
Tuberculosis
COVID-19
Infection by RNA virus
Viral Infection
Fibrotic
Fibrosis
Respiratory
Acute respiratory disorder
Asthma
Chronic obstructive pulmonary disease
Chronic pulmonary disease
Chronic respiratory disorder
Infection of respiratory tract
Inflammation of airway
Inflammation of respiratory system component
Lower respiratory tract disorder
Respiratory distress
Severe acute respiratory syndrome
Severe pulmonary disease
Non-responders only
Responders and non-responders

A


Non-responders
Responders
Size of shape proportional to number of genes
cytokine
kinase
transcription regulator
receptor
enzyme
other
LONP1
TLR3
IL1B
MT-TE
STAT1
IFN alpha
TREX1
IL1RN
USP8
RNASEH2B
MAP2K3
MAP2K6
CXCL12
TSLP
PRL
TCR
IL4
STAG2
RNY3
STAT3
NPM1
IL33
HSF1
TLR9
BTK
MMP14
TP63
IL1R2
TP53
FOXC1
SMAD1
TNF receptor
MMP12
NOX5
ARID1A
-log p-value
z-score

B


Non-responders
Responders
Size of shape proportional to number of genes
cell death
gene expression
cell/tissue development
cellular assembly or movement
blood/immune cells
other
Activation of peripheral blood neutrophils
Organization of cytoskeleton
Binding of blood cells
Movement of CD4+ T-lymphocytes
Adhesion of blood cells
Transcription
Transport of monosaccharide
Microtubule dynamics
Expression of RNA
Phosphorylation of protein
Organization of cytoplasm
Activation of cells
Cytotoxicity of cytotoxic T cells
Cell survival
Cell viability
Cellular homeostasis
Formation of cellular protrusions
Formation of nuclear foci
Growth of neurites
Quantity of superoxide
Proliferation of neural cells
-log p-value
z-score


A
Baseline
Post-Mepolizumab
PC2
PC1
60
40
20
0
-20
-100
-50
0
50
100
B
51 CpG sites hypermethylated, 2 CpG sites hypomethylated
cg09261794
cg17748184
cg16243351
cg15733917
cg13551227
cg18301742
cg26066560
cg08369629
cg14876117
$-\text{Log}_{10}\,P$
Delta beta
2.0
1.5
1.0
0.5
0.0
-0.2
-0.1
0.0
0.1
0.2
C
Row Z-Score
Baseline
Post-Mepolizumab
CpG sites


A
Baseline
Post-Mepolizumab
cg09423080
WSCD2
cg08369629
ADAM12
CAPN9
B
• correlated gene and CpG site
CAPN9:cg08369629
INPP5B:cg08369629
RP4-614O4.11:cg08369629
C1RL-AS1:cg08369629
PCDHGB7:cg26066560
RP11-1191J2.2:cg14876117
PSG5:cg09261794
SLC46A2:cg09261794
ADAM12:cg09261794
OXTR:cg22681114
GDNF-AS1:cg22681114
TRO:cg20256649
RP11-401E5.2:cg20256649
SLC46A2:cg06301443
SCN4B:cg11298262
LRRC55:cg09423080
WSCD2:cg09423080
PSG5:cg09423080
CPNE4:cg09423080
COL6A1:cg18301742
PTGFR:cg15733917
Delta beta of CpG sites
log Fold Change of gene expression
C
FOXJ1
AK7
SPEF2
TTC12
CCDC39
Primary ciliary dyskinesia
DNAAF6
DNAH11
DNAH9
NEK10
RSPH1
RSPH4A
HYDIN
DNAH1
SERPINA1
GRIN3B
Chronic familial respiratory disorder
Sinus disorder
TUBA1A
BCL2
EGFR
IL5RA
TUBB4B
Enzyme
Ion Channel
Kinase
Transcription Regulator
Transmembrane Receptor
Transporter
Other
Disease
Relationship
D
METABOLISM
Metabolism of reactive oxygen species (20)
Synthesis of reactive oxygen species (18)
Generation of reactive oxygen species (9)
Metabolism of superoxide (4)
Transport of sugar acid (3)
Transmembrane transport of ascorbic acid (2)
Uptake of ascorbic acid (2)
Gene Expression
Binding of AP1 consensus site (4)
CELLULAR MOVEMENT
Cell movement (78)
Migration of cells (66)
Stimulation of cells (10)
Cell spreading (9)
Stimulation of leukocytes (8)
Stimulation of mononuclear leukocytes (7)
Binding of muscle cells (4)
Movement of cilia (4)
Adhesion of muscle cells (3)
Calcium homeostasis of endoplasmic reticulum (3)
Migration of cd56+ natural killer cells (2)
CELLULAR ASSEMBLY
Organization of cytoplasm (54)
Organization of cytoskeleton (52)
Microtubule dynamics (47)
Formation of cellular protrusions (38)
Formation of cilia (23)
Formation of axonemes (4)
Assembly of non-motile cilium (3)
Targeting of vesicles (3)
Quantity of cytoneme (2)
CELL DEATH
Cell death of epithelial cells (12)
Apoptosis of epithelial cells (9)
Degranulation of granulocytes (4)